Skip to main content

Market Overview

Preliminary Study Finds Pfizer's COVID-19 Vaccine Effective Against UK, South Africa Variants: WSJ

  • Pfizer Inc (NYSE: PFE), in a preliminary lab study, found that its COVID-19 vaccine co-developed by BioNTech SE (NASDAQ: BNTX) is effective against the new mutation variants found in the U.K. and South Africa, the Wall Street Journal reported.
  • The new variants had only a small impact on the effectiveness of antibodies generated by the COVID-19 vaccine.
  • The study was posted on Wednesday on the bioRxiv online server and is not peer-reviewed yet.
  • The study claims that antibodies were slightly less effective against mutations in the South Africa variant.
  • Pfizer’s lab study tested only a subset of mutations found in the variants, but not the variants themselves.
  • Pfizer said that “findings do not indicate the need for a new vaccine to address the emerging variants,” but the company is prepared to respond to a vaccine-resistant version of the virus.
  • Price Action: PFE shares are down 0.52% at $36.05 in the pre-market session on the last check Thursday.

Related Articles (PFE + BNTX)

View Comments and Join the Discussion!

Posted-In: Covid-19 COVID-19 VaccineBiotech News Top Stories Media General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at